https://www.pharmanow.live/latest-news/nurexone-achieves-mbp-positive-cell-signal-exopten-spinal-cord-preclinical-program 2026-08-14T22:01:04+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 NurExone Achieves MBP-Positive Cell Signal in ExoPTEN Spinal Cord Preclinical Program https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml.globenewswire.com/Resource/Download/200ee589-52b7-47f6-aeaf-229ee0a25d0f https://www.pharmanow.live/latest-news/lantheus-fda-approval-tauklarify-tau-pet-imaging-alzheimers 2026-08-14T21:56:22+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Lantheus Gains FDA Approval for TAUKLARIFY Tau PET Imaging Agent in Alzheimer's Disease https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://www.globenewswire.com/newsroom/ti?nf=OTgxMDAzOSM3Nzc2MzIwIzIwMDc2OTA= https://www.pharmanow.live/latest-news/gland-pharma-appoints-deepak-sapra-chief-executive-officer 2026-08-14T22:02:04+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Gland Pharma Appoints Deepak Sapra as Chief Executive Officer https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b89a5945-3399-429e-b021-e4830967f08e/ed047e5a-fd00-48a5-9088-a6cf42401a3d.png https://www.pharmanow.live/latest-news/moleculin-biotech-miracle-trial-annamycin-cr-results-2027-nda 2026-08-14T21:59:44+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Moleculin Biotech Achieves Threefold CR Advantage in MIRACLE Trial Ahead of 2027 NDA Path https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b89a5945-3399-429e-b021-e4830967f08e/9c0c1b66-64c3-472c-95b2-4fca78195143.png https://www.pharmanow.live/latest-news/capricor-therapeutics-adcom-rejection-deramiocel-duchenne-cardiomyopathy 2026-08-14T21:52:31+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Capricor Therapeutics Faces 9-3 AdCom Rejection for Deramiocel in Duchenne Cardiomyopathy https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3dfe3919-c370-4bee-beac-b0e0f7056301/66967ced-a059-45ff-abfd-9b56f2624b75.png https://www.pharmanow.live/latest-news/bms-fda-accelerated-approval-iberdomide-zenbexus-multiple-myeloma 2026-08-14T16:22:27+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Bristol-Myers Squibb Gains FDA Accelerated Approval for Iberdomide in Relapsed or Refractory Multiple Myeloma https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/47824414-39ae-4f62-a25b-feea2990d20b/c37690cf-c665-469e-8109-dc4f89e6479b.png https://www.pharmanow.live/latest-news/eton-pharmaceuticals-fda-fast-track-amglidia-asn-001-nda-2027 2026-08-14T16:17:52+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Eton Pharmaceuticals Gains FDA Fast Track for AMGLIDIA and Targets 2027 NDA with ASN-001 Acquisition https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/47824414-39ae-4f62-a25b-feea2990d20b/df45f68d-20fd-4939-ab7b-a7bfdd1f3acc.png https://www.pharmanow.live/latest-news/eledon-pharmaceuticals-fda-end-of-phase-2-tegoprubart-kidney-transplant-phase-3 2026-08-14T16:19:49+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Eledon Pharmaceuticals Gains FDA End-of-Phase 2 Alignment for Tegoprubart Ahead of Global Phase 3 Kidney Trial https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/47824414-39ae-4f62-a25b-feea2990d20b/c754446e-44be-416a-aec7-6587b6757a14.png https://www.pharmanow.live/latest-news/emergent-biodefense-biothrax-fda-approval-letter-post-exposure-prophylaxis-2025 2026-08-14T16:23:41+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 Emergent BioDefense Gains FDA Approval Letter Update for BioThrax Post-Exposure Prophylaxis Labeling https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/47824414-39ae-4f62-a25b-feea2990d20b/488905a4-9cfe-4a42-8fd1-e5065cbcc91b.png https://www.pharmanow.live/latest-news/astrazeneca-anselamimab-regulatory-submission-cares-al-amyloidosis 2026-08-14T16:24:27+05:30 Pharma Now en 2026-08-14T00:00:00+05:30 AstraZeneca Plans Regulatory Submission for Anselamimab After CARES Subgroup Data Show Survival Gains https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml.globenewswire.com/media/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95/small/fortressbio1-jpg.jpg https://www.pharmanow.live/latest-news/proqr-therapeutics-axiomer-rna-editing-ax-0810-clinical-validation-2026 2026-08-14T11:59:00+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 ProQR Therapeutics Achieves First Clinical Validation of Axiomer RNA Editing Platform with AX-0810 Data https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ProQRTherapeuticsAchievesFirstClinicalValidationofAxiomerRNAEditingPlatformwithAX-0810Data20260814115849.png https://www.pharmanow.live/latest-news/karyopharm-selinexor-snda-accelerated-approval-myelofibrosis-2026 2026-08-14T12:03:51+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Karyopharm Files Selinexor sNDA in August Under Accelerated Approval for Myelofibrosis Combination https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/KaryopharmFilesSelinexorsNDAinAugustUnderAcceleratedApprovalforMyelofibrosisCombination20260814120332.png https://www.pharmanow.live/latest-news/bioneeds-india-appoints-dr-girish-joshi-chief-operating-officer 2026-08-14T12:00:20+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Bioneeds India Appoints Dr. Girish Joshi as Chief Operating Officer https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/BioneedsIndiaAppointsDr.GirishJoshiasChiefOperatingOfficer20260814115946.png https://www.pharmanow.live/latest-news/cabaletta-bio-elevate-bio-second-cdmo-rese-cel-car-t-manufacturing 2026-08-14T12:03:01+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Cabaletta Bio Selects ElevateBio as Second CDMO for Rese-cel CAR T Manufacturing https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/CabalettaBioSelectsElevateBioasSecondCDMOforRese-celCARTManufacturing20260814120251.png https://www.pharmanow.live/latest-news/biomea-fusion-opal-icovamenib-semaglutide-obesity-study-first-patient-dosed 2026-08-14T11:58:17+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Biomea Fusion Doses First Patient in OPAL Icovamenib-Semaglutide Combination Obesity Study https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/BiomeaFusionDosesFirstPatientinOPALIcovamenib-SemaglutideCombinationObesityStudy20260814115748.png https://www.pharmanow.live/latest-news/cellectar-biosciences-nda-submission-iopofosine-i131-fda-accelerated-approval-2027 2026-08-14T11:56:59+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Cellectar Biosciences Plans Mid-2027 NDA Submission for Iopofosine I 131 Under FDA Accelerated Approval https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/CellectarBiosciencesPlansMid-2027NDASubmissionforIopofosineI131UnderFDAAcceleratedApproval20260814115650.png https://www.pharmanow.live/latest-news/zealand-pharma-petrelintide-phase-3-obesity-amylin-analog-2026 2026-08-14T12:02:10+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Zealand Pharma Advances Petrelintide into Phase 3 as Amylin Analog Obesity Pipeline Expands https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ZealandPharmaAdvancesPetrelintideintoPhase3asAmylinAnalogObesityPipelineExpands20260814120159.png https://www.pharmanow.live/latest-news/allogene-cema-cel-futility-analysis-alpha3-lbcl-consolidation 2026-08-13T14:44:58+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Allogene Achieves Positive Futility Analysis for Cema-Cel in First-Line LBCL Consolidation Trial https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/AllogeneAchievesPositiveFutilityAnalysisforCema-CelinFirst-LineLBCLConsolidationTrial(1)20260813144444.png https://www.pharmanow.live/latest-news/atara-biotherapeutics-fda-type-a-meeting-tabelecleucel-bla-resubmission 2026-08-13T14:51:27+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Atara Biotherapeutics Secures FDA Type A Meeting Guidance for Tabelecleucel BLA Resubmission https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/e7d02e8a-86e5-4a1a-90fe-d8ef44be5d4a/d7552c1a-e80e-445c-84bd-1f02ea6a99e0.png https://www.pharmanow.live/latest-news/nurexone-signs-exclusive-us-gmp-manufacturing-mou-made-scientific-exosome-supply 2026-08-13T14:05:38+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 NurExone Signs Exclusive U.S. GMP Manufacturing MOU with Made Scientific for Exosome Supply https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/NurExoneSignsExclusiveU.S.GMPManufacturingMOUwithMadeScientificforExosomeSupply20260813124502.png https://www.pharmanow.live/latest-news/kura-oncology-ziftomenib-q2-2026-revenue-aml-launch 2026-08-13T14:54:00+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Kura Oncology Achieves $9.1M in Ziftomenib Revenue After Two Full Launch Quarters https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/KuraOncologyAchieves$9.1MinZiftomenibRevenueAfterTwoFullLaunchQuarters20260813124419.png https://www.pharmanow.live/latest-news/atea-pharmaceuticals-bem-rzr-phase-3-c-beyond-hcv-nda 2026-08-13T14:50:52+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Atea Pharmaceuticals Achieves Phase 3 Success for BEM/RZR Ahead of NDA Filing https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/RZRAheadofNDAFiling20260813144913.png https://www.pharmanow.live/latest-news/zealand-pharma-royalty-pharma-100-million-rusfertide-royalty-sale-2026 2026-08-13T14:05:38+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Zealand Pharma Secures USD 100 Million Royalty Sale with Royalty Pharma for Rusfertide Economics https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/NewsAI-assistedZealandPharmaSecuresUSD100MillionRoyaltySalewithRoyaltyPharmaforRusfertideEconomics(1)20260813124635.png https://www.pharmanow.live/latest-news/reviva-pharmaceuticals-fda-feedback-brilaroxazine-formulation-recover-2 2026-08-13T14:05:37+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Reviva Pharmaceuticals Awaits FDA Feedback on Brilaroxazine Formulation Change Ahead of Phase 3 RECOVER-2 Enrollment https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/RevivaPharmaceuticalsAwaitsFDAFeedbackonBrilaroxazineFormulationChangeAheadofPhase3RECOVER-2Enrollment20260813124543.png https://www.pharmanow.live/latest-news/medicus-pharma-fda-study-may-proceed-skinjekt-gorlin-syndrome-2026 2026-08-13T14:05:37+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 Medicus Pharma Gains FDA 'Study May Proceed' Authorization for SkinJect Registrational Trial in Gorlin Syndrome https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/MedicusPharmaGainsFDA'StudyMayProceed'AuthorizationforSkinJectRegistrationalTrialinGorlinSyndrome20260813123915.png https://www.pharmanow.live/latest-news/fda-anaconda-premium-500k-undeclared-tadalafil-warning 2026-08-13T14:05:37+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 FDA Confirms Anaconda Premium 500K Contains Undeclared Tadalafil, Warns Consumers Against Use https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/FDAConfirmsAnacondaPremium500KContainsUndeclaredTadalafil,WarnsConsumersAgainstUse20260813123749.png https://www.pharmanow.live/latest-news/fda-rx-to-otc-switch-list-rextovy-naloxone-june-2026 2026-08-13T14:05:37+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 FDA Updates Rx-to-OTC Switch List with Rextovy Naloxone Approval in June 2026 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/FDAUpdatesRx-to-OTCSwitchListwithRextovyNaloxoneApprovalinJune202620260813123659.png https://www.pharmanow.live/latest-news/fda-confirms-dmagic-plus-undisclosed-diclofenac-toxic-oleander-compounds 2026-08-13T14:05:36+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 FDA Confirms DMagic Plus Contains Undisclosed Diclofenac and Toxic Oleander Compounds https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/FDAConfirmsDMagicPlusContainsUndisclosedDiclofenacandToxicOleanderCompounds20260813123614.png https://www.pharmanow.live/latest-news/fda-confirms-b-magi-weight-loss-supplement-contains-undeclared-toxic-yellow-oleander-derivatives 2026-08-13T14:05:36+05:30 Pharma Now en 2026-08-13T00:00:00+05:30 FDA Confirms B. Magi Weight-Loss Supplement Contains Undeclared Toxic Yellow Oleander Derivatives https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/FDAConfirmsB.MagiWeight-LossSupplementContainsUndeclaredToxicYellowOleanderDerivatives20260813123540.png https://www.pharmanow.live/latest-news/madrigal-pharmaceuticals-appoints-john-c-reed-board-director-mash-pipeline 2026-08-13T19:44:15+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Madrigal Pharmaceuticals Appoints John C. Reed as Director to Strengthen MASH Pipeline Leadership https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/432d2d23-d471-4fcb-883d-3a242c7a273e/7391ed21-6d0a-484e-b3e8-209f0efda94e.png https://www.pharmanow.live/latest-news/mineralys-therapeutics-lorundrostat-nda-fda-pdufa-december-2026 2026-08-13T14:05:32+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Mineralys Therapeutics Advances Lorundrostat NDA Toward December 2026 FDA PDUFA Date https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/MineralysTherapeuticsAdvancesLorundrostatNDATowardDecember2026FDAPDUFADate20260812125124.png https://www.pharmanow.live/latest-news/inhibikase-therapeutics-fda-orphan-drug-designation-ikt-001-pulmonary-arterial-hypertension 2026-08-13T14:05:31+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Inhibikase Therapeutics Gains FDA Orphan Drug Designation for IKT-001 in Pulmonary Arterial Hypertension https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/39c03d22-0a3d-4003-bd1c-3fc64fd7060c/4864d5ce-56ec-4d11-a86a-59760adafe16.png https://www.pharmanow.live/latest-news/aquestive-therapeutics-anaphylm-nda-resubmission-q3-2026-crl-remediation 2026-08-13T14:05:31+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Aquestive Therapeutics Completes CRL Remediation Studies for Anaphylm NDA Resubmission in Q3 2026 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/AquestiveTherapeuticsCompletesCRLRemediationStudiesforAnaphylmNDAResubmissioninQ3202620260812125028.png https://www.pharmanow.live/latest-news/bolt-biotherapeutics-bdc-4182-isac-cohort-4-q3-2026-data 2026-08-13T14:05:31+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Bolt Biotherapeutics Advances BDC-4182 ISAC to Cohort 4 with Initial Data Due Q3 2026 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/BoltBiotherapeuticsAdvancesBDC-4182ISACtoCohort4withInitialDataDueQ3202620260812125300.png https://www.pharmanow.live/latest-news/genentech-ai-oncology-strategy-anwesha-dey 2026-08-12T12:12:18+05:30 Pharma Now en 2026-08-12T12:12:16+05:30 Genentech's AI-Driven Oncology Strategy: Inside the Vision of a Distinguished Scientist https://gene.com/assets/content/tile_image/press-release.jpg https://www.pharmanow.live/latest-news/eupraxia-pharmaceuticals-advances-diffusphere-platform-phase-3-eoe-trial-ddw-data 2026-08-13T14:05:31+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Eupraxia Pharmaceuticals Advances Diffusphere Platform Toward Phase 3 EoE Trial Following DDW Data https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/EupraxiaPharmaceuticalsAdvancesDiffuspherePlatformTowardPhase3EoETrialFollowingDDWData20260812125426.png https://www.pharmanow.live/latest-news/codexis-eco-synthesis-gmp-facility-fda-engagement-2026 2026-08-13T14:05:30+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Codexis Advances ECO Synthesis Platform Toward GMP Facility Build-Out and FDA Engagement in 2026 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/CodexisAdvancesECOSynthesisPlatformTowardGMPFacilityBuild-OutandFDAEngagementin202620260812125520.png https://www.pharmanow.live/latest-news/janssen-fda-approval-icotyde-oral-il-23-receptor-antagonist-plaque-psoriasis 2026-08-13T14:05:30+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 Janssen Gains FDA Approval for ICOTYDE, First Oral IL-23 Receptor Antagonist in Plaque Psoriasis https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/JanssenGainsFDAApprovalforICOTYDE,FirstOralIL-23ReceptorAntagonistinPlaquePsoriasis20260812125551.png https://www.pharmanow.live/latest-news/fda-otc-monograph-omufa-reauthorization-fy2026-2030 2026-08-13T14:05:30+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 FDA Updates OTC Monograph Framework as OMUFA Reauthorization Covers Fiscal Years 2026 to 2030 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/FDAUpdatesOTCMonographFrameworkasOMUFAReauthorizationCoversFiscalYears2026to203020260812125714.png https://www.pharmanow.live/latest-news/fda-confirms-detoxi-slim-undeclared-sibutramine-2026 2026-08-13T14:05:30+05:30 Pharma Now en 2026-08-12T00:00:00+05:30 FDA Confirms Detoxi Slim Contains Undeclared Sibutramine in Renewed 2026 Laboratory Testing https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/FDAConfirmsDetoxiSlimContainsUndeclaredSibutramineinRenewed2026LaboratoryTesting20260812125756.png